Experts in multiple myeloma management discuss the use of MRD as primary endpoint for clinical trials, its potential as a treatment goal, and its applicability in clinical decision-making. The pros and cons of flow cytometry vs. next generation sequencing for MRD testing are explored, along with the importance of sensitivity and standardization. Available methods for managing multiple myeloma and the role of adherence in determining standardization are discussed. Efforts to standardize the use of flow in laboratories worldwide, improve reproducibility of data, and establish a quality control system are also highlighted.